Take the case of the Sickle Cell anemia disease, (SCAD), another Malaria related disease. Last year, a small company in Nigeria (XECHEM Nigerian pharmaceutical Ltd) discovered the most effective treatment for SCAD to date. For a disease that affects over 1 million African-Americans, (and every child born in DC and other places is screened for it), such a good new coming from Africa did not make any news in this country. The popular Economic magazine, The Economist, in its February 1st, 2007 edition sums it up like this, and I quote: “Good science does get done in Africa, though it tends to go unnoticed”. It also means that thousands of African-American children with SCAD are still treated and managed with the old ineffective treatments prescribed by the big Drug companies. The issue of Sickle cell is very personal to me. My father had it. In fact that was the main reason, I became a pharmacist. My father was always sick when I was young. I did not know why but I wanted to help him stop the pain. This led to my interest in Chemistry, taught by an American Peace Corp, who encouraged me to study Pharmacy. Unfortunately, my father died a month after I graduated from Pharmacy. So, whenever I come across any patients with SCAD in the Hospitals or Clinics, I am always extra supportive and nicer to them. Also, 2 out of our 4 children inherited the sickle cell trait from me, just as predicted by statistics. Hence, I am very passionate about SCAD. PharmAfric intends to work with such Africa-based pharmaceutical company to find treatments and cures for African diseases that also affect African-Americans. Good science will still get done in Africa, and now PharmAfric will make sure that they’re noticed.
Market Data 
Markets 
AI
